Kuros Biosciences signs new agreements

Image credit: Harlie Raethel

Kuros Biosciences has signed sales and distribution agreements for MagnetOs bone graft with various companies. According to a press release, these cover Switzerland, the Netherlands, Austria and Finland

Kuros has given Lubbers Medical BV non-exclusive rights to sell MagnetOs in the Netherlands, effective from the fourth quarter of 2020. Exclusive stocking distributor agreements for Switzerland and Austria have been signed with Orthocontor AG and Amacord GmbH, respectively. Both agreements will already come into effect in the current quarter.

For Finland, a letter of intent has been signed with Arthrone Oy. The company from Schlieren expects to sign a full stocking distributor agreement for Finland by the end of the second quarter of 2021. These add to an existing agreement in the UK and Ireland. MagnetOs bone grafts were first used in the UK in May 2017.

Joost de Bruijn, Chief Executive Officer of Kuros, said: “We are pleased to finalize these sales and distribution agreements, which recognize the unique osteoinductive properties of MagnetOs, with respected partners across Northern Europe following a competitive process. Sales of MagnetOs are accelerating, and these agreements will enable further expansion.”

Kuros Biosciences specializes in the development of solutions for targeted and controlled bone healing and soft tissue regeneration. It is a spin-off from the University of Zurich (UZH) and the Swiss Federal Institute of Technology in Zurich (ETH). The company’s headquarters are based in Bio-Technopark Schlieren-Zürich. gba